Treatment of Giant Cell Arteritis and Takayasu Arteritis-Current and Future
B Hellmich1, A F Águeda2, S Monti3,4
1Klinik für Innere Medizin, Rheumatologie und Immunologie, Vaskulitis-Zentrum Süd, Medius Kliniken, akademisches Lehrkrankenhaus der Universität Tübingen, Kirchheim-unter-Teck, Germany. b.hellmich@medius-kliniken.de.
Insights
Giant cell arteritis (GCA) and Takayasu arteritis (TA) management guidelines are updated. Tocilizumab shows promise as a glucocorticoid-sparing therapy for GCA, while evidence for TA treatments is still emerging.
Area of Science:
- Rheumatology
- Immunology
- Internal Medicine
Background:
- Large vessel vasculitides, including giant cell arteritis (GCA) and Takayasu arteritis (TA), require updated management strategies.
- Glucocorticoids (GCs) are standard for remission induction but lead to significant side effects due to prolonged use.
- GC-sparing therapies are crucial for long-term patient management.
Purpose of the Study:
- To review current treatment recommendations for GCA and TA.
- To evaluate emerging therapeutic strategies for these conditions.
- To address gaps in evidence-based treatment for TA.
Main Methods:
- Systematic review of recent guidelines and high-quality evidence.
- Analysis of the efficacy of established and novel immunomodulatory agents.
- Evaluation of glucocorticoid-sparing potential of various treatments.
Main Results:
- Tocilizumab demonstrates efficacy as a glucocorticoid-sparing agent in GCA, particularly for relapsing disease.
- Methotrexate is recommended as a GC-sparing option for selected GCA patients and all TA patients.
- Non-biologic and biologic immunomodulators show potential GC-sparing effects in TA.
- High-quality evidence for TA treatment remains limited.
Conclusions:
- Tocilizumab is now a standard treatment option for GCA, though optimal use requires further study.
- GC-sparing strategies are essential for managing GCA and TA.
- Further research is needed to establish robust treatment guidelines for Takayasu arteritis.
Purpose Of Review:
Guidelines for the management of large vessel vasculitides have been recently updated by several scientific societies. We have evaluated the current recommendations for treatment of giant cell arteritis (GCA) and Takayasu arteritis (TA) and addressed potential future therapeutic strategies.
Recent Findings:
While glucocorticoids (GCs) remain the gold standard for induction of remission, many patients relapse and acquire high cumulative GC exposure. Thus, GC-sparing therapies such as methotrexate are recommended for selected patients with GCA and all patients with TA. Recent high-quality evidence shows that tocilizumab is an effective GC-sparing agent in GCA. Non-biologic and biologic immunomodulators also appear to have GC-sparing properties in TA. Tocilizumab is now considered to be part of the standard treatment for GCA, particularly with relapsing disease, but questions on its use such as length of treatment and monitoring of disease activity remain open. High-quality evidence to guide treatment of TA is still lacking.
Related Concept Videos
01:21Rheumatic Heart Disease III: Medical Management
01:26Atherosclerosis III: Management
01:14Myocarditis III: Medical Management
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:17Pericarditis III: Medical Management
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...